Which statement about the relationship between troponin T testing and CK-MB is supported by these materials?

Which statement about the relationship between troponin T testing and CK-MB is supported by these materials?

• A. Troponin T testing is most valuable after CK-MB has peaked and returned to baseline
• B. Troponin T testing is only useful before CK-MB peaks
• C. Troponin T testing replaces CK-MB completely in all scenarios
• D. Troponin T testing has no relation to CK-MB dynamics

Answer: (A)

The key idea is the different timing of release and clearance for CK-MB and troponin T after heart muscle injury. CK-MB rises early, peaks around about a day, and then returns toward baseline within a couple of days. Troponin T also rises within hours, but it stays elevated much longer, often for a week or more. Because of this, troponin T testing adds diagnostic value after CK-MB has already peaked and returned toward baseline. If CK-MB has normalized but a myocardial injury has occurred recently, troponin T can still be elevated and confirm the injury. This makes troponin especially useful in patients who present later or in cases where CK-MB results have become noninformative due to normalization. Other statements don’t fit the pattern: troponin is not solely useful before CK-MB peaks, it does not completely replace CK-MB in all scenarios, and there is indeed a relationship between their dynamics—they rise and fall on different timelines, which is why measuring troponin after CK-MB has normalized is particularly informative.

The key idea is the different timing of release and clearance for CK-MB and troponin T after heart muscle injury. CK-MB rises early, peaks around about a day, and then returns toward baseline within a couple of days. Troponin T also rises within hours, but it stays elevated much longer, often for a week or more.

Because of this, troponin T testing adds diagnostic value after CK-MB has already peaked and returned toward baseline. If CK-MB has normalized but a myocardial injury has occurred recently, troponin T can still be elevated and confirm the injury. This makes troponin especially useful in patients who present later or in cases where CK-MB results have become noninformative due to normalization.

Other statements don’t fit the pattern: troponin is not solely useful before CK-MB peaks, it does not completely replace CK-MB in all scenarios, and there is indeed a relationship between their dynamics—they rise and fall on different timelines, which is why measuring troponin after CK-MB has normalized is particularly informative.